Tirzepatide
Also known as: Mounjaro, Zepbound, GIP/GLP-1 dual agonist
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
A dual GIP and GLP-1 receptor agonist with FDA approvals for type 2 diabetes and chronic weight management, supported by large randomized trials.
What it is & how it works
What it is
Tirzepatide is a dual agonist: a single molecule that activates two gut-hormone receptors at once — GIP and GLP-1. It’s sold as Mounjaro for type 2 diabetes, Zepbound for weight management, and carries an approval for obstructive sleep apnea in obesity. If semaglutide proved the GLP-1 concept, tirzepatide is the proof that stacking incretin pathways can push the numbers higher.
How it works
GLP-1 and GIP are both incretin hormones — gut signals that amplify insulin release after eating. Semaglutide engages one of them; tirzepatide engages both. The practical result is the same three-part effect — glucose-dependent insulin secretion, slowed gastric emptying, reduced appetite — but the dual mechanism appears to compound it. The GIP arm is the conceptual differentiator, and the same logic of “add another receptor” is what carries forward into the triple agonist retatrutide.
The evidence — including the head-to-head
The SURPASS program covered diabetes and the SURMOUNT program covered weight, with SURMOUNT-1 showing average reductions in the low-20% range at the top dose — meaningfully above semaglutide’s STEP figures. More importantly, SURMOUNT-5 was a direct head-to-head against semaglutide, and tirzepatide came out ahead on average weight loss. Direct comparator trials are rare and valuable; this one is why tirzepatide is widely regarded as the current leader among approved agents.
The honest caveats
The dual mechanism doesn’t come free: gastrointestinal side effects are the dominant issue, which is exactly why the approved products titrate slowly over months rather than starting at an effective dose. It carries the same class warnings as semaglutide, including the boxed thyroid C-cell tumor warning derived from rodent studies. And like semaglutide, weight tends to return after stopping — this is ongoing therapy, not a fixed course.
Where it stands, and the gray-market footnote
Among approved drugs, tirzepatide currently sits at the top of the weight-effect table. That status, plus shortages and cost, fueled a large compounded and research-market supply — a recurring FDA enforcement subject, with the usual identity, dosing, and sterility risks that the trials simply do not speak to. The clean version of this story is a prescription medicine with an unusually strong evidence base; the messy version is everything happening around it on the unregulated market.
What it's discussed & studied for
- Type 2 diabetes (approved)
- Chronic weight management (approved)
- Obstructive sleep apnea in obesity (approved)
Discussion of a use is not a claim that it works or is approved.
Research status
FDA-approved and backed by the SURPASS (diabetes) and SURMOUNT (weight) randomized trial programs, including a head-to-head trial against semaglutide.
Evidence quality
High: large randomized controlled human trials, including active-comparator studies against GLP-1-only agents.
Dosing discussion
Approved products use a stepwise titration to limit gastrointestinal effects. Dosing belongs with a prescribing clinician and the label, not community protocols.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
Side effects are predominantly gastrointestinal. It carries labeled warnings (including a boxed thyroid C-cell tumor warning from rodent data). Prescription drug — use under supervision.
Sourcing literacy
Approved tirzepatide is prescription-only. Gray-market or compounded versions are a recurring FDA enforcement subject and carry identity/purity/dosing risk.
Selected literature
FAQ
What makes tirzepatide 'dual'?
It activates both the GIP and GLP-1 receptors, whereas semaglutide targets GLP-1 alone. In trials this dual action produced strong glucose and weight effects.
Is it approved?
Yes — for type 2 diabetes (Mounjaro), chronic weight management (Zepbound), and obstructive sleep apnea in obesity.
Is tirzepatide better than semaglutide?
In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater average weight loss. 'Better' still depends on the individual, tolerability, cost and access — but on the weight number, it led.